



For release: 8 June 2009

Xention Limited Builds Team with Appointment of Chief Medical Officer

CAMBRIDGE, UK – XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today the appointment of Dr Patrick Round as Chief Medical Officer and Head of Development.

Dr Round has broad and substantial experience in development in both biotech and pharma, most notably as Senior Vice President at Cambridge Antibody Technology (CAT) where he was responsible for all aspects of development including manufacturing, process development, quality, regulatory, clinical development and project management. He was a member of the CAT leadership team responsible for the day to day running of the company and chaired the product steering committee responsible for project governance and oversight of the discovery and development interface.

Previously, Dr Round was Director of Development at Celltech R&D, Director of Clinical Development at Glaxo Wellcome and clinical project manager at Novo Nordisk Pharmaceuticals. He has also served as Chief Medical Officer at Phoqus Pharmaceuticals.

“We are delighted that Patrick has joined us in this very crucial role” commented Tim Brears, Xention’s Chief Executive. “His many years of experience in senior executive roles in both large pharma and biotech will be invaluable as our clinical activities broaden and gain momentum. We have important clinical objectives to meet over the next couple of years and Patrick’s guidance will be essential as we build substantial value in our clinical assets. He comes to us with outstanding credentials and we look forward to his playing a key role in our management team”.



For further information, please contact:

Tim Brears
CEO
Xention Limited

+44 (0)1223 493 900

Anna Dunphy
De Facto Communications

+44 (0)20 7861 3838

Notes to Editors:

Xention Ltd is a leader in the discovery and development of ion channel-modulating drugs. The Company's potential breakthrough drugs in clinical development include XEN-D0101, a new atrial selective potassium channel blocker for atrial fibrillation, and XEN-D0501, a novel ion channel modulator for the treatment of overactive bladder. Xention also has preclinical research programmes in atrial fibrillation, pain and autoimmune disease. The Company uses proprietary ion channel expertise and technologies to accelerate the discovery of potent and selective ion channel drugs. In particular, Xention is a leader in the use of true electrophysiological data, ion channel chemoinformatics and experienced medicinal chemistry to identify potent new small molecule drugs in this rapidly evolving field of medicine. For further information, please see their website <http://www.xention.com>.

Xention Limited, Iconix Park
London Road, Pampisford
Cambridge CB22 3EG

Tel: +44 (0)1223 493900
Fax: +44 (0)1223 493901
www.xention.com